Abstract:Rapamycin is a triene macrolide antibiotic produced by Streptomyces hygroscopicus. Besides its wide application as an effective immunosuppressive agent, other important bioactivities have made rapamycin a potential drug lead for novel pharmaceutical development. However, the low titer of rapamycin in the original producer strain limits further industrialization efforts and restricts its use for other applications. Predicated on knowledge of the metabolic pathways related to rapamycin biosynthesis in S. hygroscopicus, we have rationally designed approaches to generate a rapamycin high producer strain of S. hygroscopicus HD-04-S. These have included alleviation of glucose repression, improved tolerance towards lysine and shikimic acid, and auxotrophy of tryptophan and phenylalanine through the application of stepwise UV mutagenesis. The resultant strain produced rapamycin at 450 mg/L in the shake flask scale. These fermentations were further scaled up in 120 and 20,000 L fermentors, respectively, at the pilot plant. Selected fermentation factors including agitation speed, pH, and on-line supplementation were systematically evaluated. A fed-batch strategy was established to maximize rapamycin production. With these efforts, an optimized fermentation process in the larger scale fermentor was developed. The final titer of rapamycin was 812 mg/L in the 120 L fermentor and 783 mg/L in the 20,000 L fermentor. This work highlights a high rapamycin producing strain derived by mutagenesis and subsequent screening, fermentation optimization of which has now made it feasible to produce rapamycin on an industrial scale by fermentation. The strategies developed here should also be applicable to titer improvement of other important microbial natural products on an industrial scale. Biotechnol. Bioeng. 2010; 107: 506-515. (C) 2010 Wiley Periodicals, Inc.

Development of an Economical Fermentation Platform for Enhanced Ansamitocin P-3 Production in Actinosynnema Pretiosum

Rational Approach to Improve Ansamitocin P‐3 Production by Integrating Pathway Engineering and Substrate Feeding in Actinosynnema Pretiosum

Improvement of Ansamitocin P-3 Production by Actinosynnema mirum with Fructose as the Sole Carbon Source

Combination of Traditional Mutation and Metabolic Engineering to Enhance Ansamitocin P-3 Production in Actinosynnema pretiosum.

Enhancement of Ansamitocin P-3 Production in Actinosynnema Pretiosum by a Synergistic Effect of Glycerol and Glucose

Metabolomics Analysis of Actinosynnema Pretiosum with Improved AP-3 Production by Enhancing UDP-glucose Biosynthesis.

Metabolomic change and pathway profiling reveal enhanced ansamitocin P-3 production in Actinosynnema pretiosum with low organic nitrogen availability in culture medium

Enhanced production of ansamitocin P-3 by addition of isobutanol in fermentation of Actinosynnema pretiosum.

Enhancement of UDPG Synthetic Pathway Improves Ansamitocin Production in Actinosynnem Pretiosum

Efflux identification and engineering for ansamitocin P-3 production in Actinosynnema pretiosum

Identification and engineering of post-PKS modification bottlenecks for ansamitocin P-3 titer improvement in Actinosynnema pretiosum subsp. pretiosum ATCC 31280.

Effect of ammonium in medium on ansamitocin P-3 production by Actinosynnema pretiosum

Increased yield of AP-3 by inactivation of asm25 in Actinosynnema pretiosum ssp. auranticum ATCC 31565

Effects of the Methylmalonyl-CoA Metabolic Pathway on Ansamitocin Production in Actinosynnema Pretiosum

Proteomic Studies on Anti-Tumor Agent Ansamitocin P-3 Producer Actinosynnema Pretiosum in Response to Ammonium and Isobutanol

Generation of high rapamycin producing strain via rational metabolic pathway-based mutagenesis and further titer improvement with fed-batch bioprocess optimization.

Optimization of fermentation conditions for production of a novel antifungal metabolite by response surface methodology

Genome-Scale Metabolic Model of Actinosynnema Pretiosum ATCC 31280 and Its Application for Ansamitocin P-3 Production Improvement.

Enhanced production of ansamitocin P-3 by addition of Mg 2+ in fermentation of Actinosynnema pretiosum

Preparative Isolation and Purification of Anti-Tumor Agent Ansamitocin P-3 from Fermentation Broth of Actinosynnema Pretiosum Using High-Performance Counter-Current Chromatography.

Biosynthesis of ansamitocin P-3 incurs stress on the producing strain Actinosynnema pretiosum at multiple targets